FILE PHOTO: A trader works by the post that trades AbbVie on the floor of the New York Stock Exchange March 5, 2015. AbbVie Inc said on Thursday it fought two other drugmakers to “the bitter end” to buy Pharmacyclics Inc and its hot-selling Imbruvica cancer drug, and expects the medicine to generate eventual peak annual sales of more than $7 billion.REUTERS/Brendan McDermid